As I look ahead to 2026 and search for compelling investment opportunities, one productive place to focus is on stocks that lagged during an otherwise strong year for U.S. equities. The broader market notched its third consecutive double-digit gain, yet beneath the surface, performance was far from uniform.
Source: https://www.zacks.com/commentary/2811011/3-beaten-down-stock…
US stocks opened mixed on Thursday as Oracle’s troubling earnings report spooked investors despite the Federal Reserve’s dovish rate cut just a day earlier. The S&P 500 fell 0.3%, unable to hold Wednesday’s momentum near record highs, while the tech-heavy Nasdaq Composite retreated 0.7%, reflecting broader concerns about AI spending sustainability.
DraftKings’ bulls were thrown an unexpected curveball, but this new competition doesn’t carry the same brand-name cache. After years of development, Recursion Pharmaceuticals’ AI-powered drug discovery technology should finally, firmly start proving its true value.
The slide this month by Oracle (ORCL) and Broadcom (AVGO) has reminded investors that artificial intelligence (AI) stocks don’t move up in a straight-line fashion. They may also want to consider that prior pullbacks by mega-cap AI equities have often proven to be buying opportunities.
